|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||12.81 - 13.42|
|52 Week Range||10.77 - 23.55|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 13, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.00|
TELA Bio, Inc. (TELA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ladies and gentlemen, thank you for standing by, and welcome to the TELA Bio fourth quarter earnings conference call. Earlier today, TELA Bio released financial results for the fourth quarter and year ended December 31, 2020. Joining me on today's call are Tony Koblish, president and CEO; and Nora Brennan, CFO.
MALVERN, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the company will report first quarter ended March 31, 2021, financial results on Thursday, May 13, 2021. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast DetailsThe conference call can be accessed by dialing 855-548-1219 for participants in the U.S. or Canada and 409-217-8881 for international callers, using conference ID 7381947. A live and archived webcast of the event can be accessed via the Events & Presentations page of the investor section of TELA's website. About TELA Bio, Inc.TELA Bio Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company is committed to providing advanced, economically effective biologic material repair solutions to patients to minimize long-term exposure to permanent synthetic materials and improve clinical outcomes. TELA Bio’s OviTex® and OviTex PRS Reinforced Tissue Matrix products are purposefully designed to address the shortcomings of existing reinforcement materials in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. For more information, visit www.telabio.com. Investor ContactGreg Chodaczek347-620-7010 firstname.lastname@example.org